Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowNet Cash FlowNet IncomeShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Avidity Biosciences (RNA) Change in Acquisitions & Divestments: 2021-2024

Historic Change in Acquisitions & Divestments for Avidity Biosciences (RNA) over the last 4 years, with Dec 2024 value amounting to $586.4 million.

  • Avidity Biosciences' Change in Acquisitions & Divestments rose 90.20% to $269.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $1.1 billion, marking a year-over-year increase of 141.42%. This contributed to the annual value of $586.4 million for FY2024, which is 74.96% up from last year.
  • Per Avidity Biosciences' latest filing, its Change in Acquisitions & Divestments stood at $586.4 million for FY2024, which was up 74.96% from $335.2 million recorded in FY2023.
  • Over the past 5 years, Avidity Biosciences' Change in Acquisitions & Divestments peaked at $586.4 million during FY2024, and registered a low of $6.6 million during FY2021.
  • Its 3-year average for Change in Acquisitions & Divestments is $363.4 million, with a median of $335.2 million in 2023.
  • Data for Avidity Biosciences' Change in Acquisitions & Divestments shows a peak YoY spiked of 2,463.91% (in 2022) over the last 5 years.
  • Yearly analysis of 4 years shows Avidity Biosciences' Change in Acquisitions & Divestments stood at $6.6 million in 2021, then skyrocketed by 2,463.91% to $168.7 million in 2022, then skyrocketed by 98.67% to $335.2 million in 2023, then spiked by 74.96% to $586.4 million in 2024.